

Investment Profile


1. Capital-light funding model providing significantly greater benefits to value realisations
2. Proactive, 'hands-on' management
3. Continued judicious direct investments and advisory services
4. Trebled portfolio with multiple prospects for realising returns
5. Trading at significant discount to fair market value
6. Well structured for growth and targeted expansion

Share Information

Ticker	AIM: NSCI
Share Price (GBX)	59
Shares in issue (m)	21
Market Cap (£m)	12
12m Hi/Low (GBX)	209/47

(Source: The London Stock Exchange, March 2022)

12-Month Share Price



(Source: The London Stock Exchange, March 2022)

Major Shareholders (as of March 2022)

Name	%
Futura Messis Group Ltd.	17.15
AB Group Ltd.	16.25
Zahra Holdings Ltd.	5.14
Canaccord Genuity Group Inc.	4.88

(Source: company website)

Company Overview

NetScientific plc (AIM: NSCI) invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offers significant global growth potential predominately in the UK and USA. The Group leverages trans-Atlantic relationships and global opportunities to deliver shareholder value.

The Group's portfolio has nearly trebled since 2020, from 8 to 23 companies, either as direct subsidiaries, direct or advised investments (through capital under advisory), varying from start-up private companies to publicly listed equities.

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group's proactive approach drives portfolio companies through value inflection points, and works towards the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong trans-Atlantic and growing international presence, with investments in the US, UK, EU and Israel, providing attractive expansion prospects.

NSCI operates a capital-light investment structure that uses its balance sheet and PLC brand to achieve a multiplier effect when investing in portfolio companies. This combines NSCI's balance sheet to anchor and support investments, syndicated investments through its corporate finance subsidiary EMV Capital, and soft funds from corporate collaborations and public sector grants.

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

Investment Approach

The Company's strategy is geared to maximising shareholder value from its portfolio companies by:

- Realigning the market capitalisation with the company's strong underlying asset value;
- Building the NSCI platform resources and infrastructure to accelerate the growth potential of the subsidiaries and portfolio companies;
- Delivering shareholder returns by driving the business development and expansion plans through appropriate key value inflection points to create profitable liquidity events and exits.

What's New?

Since raising £7.7m in June 2021, the Company has focused on further growing its portfolio size and value, highlighted through several transactions. It has strategically invested in [Martlet Capital](#), a portfolio of minority interests in the Cambridge high-tech cluster, [Sageteck](#), a platform for the capture, extraction and purification of volatile anaesthetic agents from patient exhalation, [Q Bot, a robotics company](#) that provides a semi-automated, under-floor insulation service, [Epibone, a US based bone and cartilage regenerative therapy company](#), and the [75% acquisition of Cetromed](#), a life sciences holding company with a number of companies spun out of the University of Leuven, Belgium.

Diversified Portfolio



NetScientific's key portfolio companies and subsidiaries include the following:

- ProAxis:** A commercial-stage diagnostics organisation, based in Northern Ireland, with a rapidly growing client list of pharmaceutical companies and academic laboratories. The Company promotes a range of assay kits designed for the specific measurement of active protease biomarkers of disease. Its easy-to-use tests incorporate patented "ProteaseTags®"; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.
- Glycotest:** A liver disease diagnostics company commercialising new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. Founded in 2012 by NetScientific on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine, they have exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals. The Company's lead test for curable early-stage liver cancer has significantly outperformed the current standard blood test in multiple preliminary clinical studies.
- EMV Capital (EMVC):** EMV Capital is a London-based, award winning investment advisory and venture capital firm with a focus on sustainability, industrials and healthcare. EMV Capital's model is to syndicate investments between financial and corporate investors, and to take a hands-on role post-investment with a focus on venture capital-type returns. It works alongside NetScientific to develop a customised investment strategy for each portfolio company and provides access to a blend of private, corporate and institutional finance sources. These syndicated investments contribute to Capital Under Advisory with a carry fee model.
- PDS Biotechnology (NASDAQ: PDSB):** PDS is a biotech company with a dual focus on cancer immunotherapy and vaccines for infectious diseases (including Influenza and COVID), with three Phase 2 trials with Merck, National Cancer Institute and MD Anderson. The Company's platform Versamune® has the ability to train the immune system to effectively induce adequate numbers of powerful disease-attacking CD8+ killer T-cells, and to overcome the tumor's ability to evade or suppress T-cell attack. NetScientific backed the company as a University spin-out, and more recently participated in several NASDAQ placements, alongside fund-raises led by major US investment banks.

Meet NetScientific plc

To view NetScientific's latest results presentation, register with **Investor Meet Company** by [clicking here](#)

To receive the Company's newsletter, register at: newsletter@netscientific.net



Key Newsflow

Feb: [PDS Clinical Trial with Mayo Clinic and Phase 2 Trial Update](#)

Jan: [PDS Announces Preclinical Data for PDS0202 Vaccine and Grant for Novel HPV16 Immunotherapy Patent](#)

Jan 2022: [ProAxis CEO End of Year Update](#)

Dec 2021: [NetScientific takes 19% direct stake in Q-Bot](#)

Dec: [Acquisition of majority 75% stake in Cetromed Ltd](#)

Dec: [EMVC syndicates additional £0.73m investment into Martlet Capital](#)

Dec: [\\$1million investment into portfolio company, Epibone](#)

Nov & Oct: [Sofant Signs EUR7.3m ESA Contract and EMV Capital Participates in £843k Sofant Funding](#)

Oct: [ProAxis announces the approval of a key US patent](#)

Management Team

Dr. Ilian Iliev, Chief Executive Officer

Ilian joined NetScientific PLC as CEO in 2020 to lead the company's turnaround, after the Company acquired EMV Capital, a company he founded and led. He is an experienced investor and executive in growth and technology companies in sustainability, MedTech and industrials. He founded CambridgeIP (2006-2012), a provider of IP strategy and technology intelligence services. Ilian holds a PhD from Cambridge University with a focus on Venture Capital.

John Clarkson, Executive Chairman

John is an experienced business professional and qualified accountant, with a successful career in the UK and overseas, including ex PWC Partner in Charge of the Development Services Consultancy Division, CEO of a US start-up, Chairman of a Technology Company and Vice Chairman of Laura Ashley Inc. Leading a worldwide remit for restructuring, cost reduction and business turnaround, John brings many years of commercial expertise in leadership roles.

Professor Stephen Smith, Non-Executive Director

Stephen joined the Board in February 2016 and has held senior leadership roles in the NHS, academia and commercial businesses. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO with the University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust. He is also the Chairman of the Remuneration and Nomination Committees.

Clive Sparrow, Non-Executive Director

Clive joined the NetScientific Board in December 2020 and is chair of the audit committee. He is also a Non-Executive Director serving on the board of the largest community healthcare NHS Trust in London. He has a proven track record in strategy development, transformational change, risk management and performance improvement. His specialities are government, the NHS, regulation, governance and finance.

The Value Opportunity

Strong upside with 180p consensus valuation - research available from [WH Ireland](#) and [Proactive Investors](#). This valuation is also reiterated by the Investor Chronicle's Simon Thompson, [who regularly covers NetScientific](#).